It also does the same as Aduhelm, which is to say it does nothing to halt AD. This is a media blitz to help prepare it to have positive coverage before it goes before the FDA. Biogen hopes that it also causes the public to force the FDA to approve this drug like they did with Aduhelm. This is just another incredibly expensive placebo that needs to be infused directly into brain CSF, and gives 1 in 5 people a brain bleed.